Discovery of HMPL-306 (Ranosidenib), a New Potent and Selective Dual Inhibitor of Mutant IDH1 and 2 in Clinical Development for Cancer Treatment
HMPL-306(Ranosidenib)是一种新型高效选择性突变型IDH1和IDH2双重抑制剂,目前正处于癌症治疗的临床开发阶段。
期刊:ACS Medicinal Chemistry Letters
影响因子:4
doi:10.1021/acsmedchemlett.4c00625
Xiao, Kun; Zhang, Zheng; Wu, Yao; Li, Gang; Chen, Jia; Ren, Yongxin; Yang, Na; Zhou, Jinghong; Zhang, Wei; Wang, Jian; Zhong, Zeyu; Xia, Sumei; Wang, Guanglin; Li, Na; Li, Wenji; Feng, Ling; Zhang, Weihan; Su, Weiguo; Dai, Guangxiu